Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes - PubMed
3 months ago
- #Empagliflozin
- #Inflammation
- #Myocardial Infarction
- Empagliflozin (EMPA) shows timing-dependent anti-inflammatory effects in monocyte-derived macrophages (MDMs) from type 2 diabetes (T2DM) patients post-myocardial infarction (AMI).
- Early EMPA administration reduces NLRP3 inflammasome activity (IL1β mRNA, caspase-1) and pro-inflammatory cytokines (TNFα, IL6, MCP1) in MDMs.
- EMPA may lower residual cardiovascular risk by modulating inflammatory and senescence pathways (p21, IL8, BCL2) in macrophages.
- Study involved 66 T2DM-AMI patients randomized to early (discharge) or delayed (90-day) EMPA treatment, with samples collected over 180 days.
- Findings support immediate post-AMI EMPA use to reduce inflammation, warranting further clinical investigation.